NCT00501449

Brief Summary

The specific aims of the study include:

  1. 1.Profile the demographic, health-related, psychosocial and behavioral characteristics of adults with MEN1 or MEN2.
  2. 2.Evaluate MEN-specific distress as well as adherence to surveillance regimens among adults with MEN1 or MEN2, and identify associated with those outcomes.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
133

participants targeted

Target at P50-P75 for all trials

Timeline
Completed

Started May 2007

Longer than P75 for all trials

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

May 1, 2007

Completed
2 months until next milestone

First Submitted

Initial submission to the registry

July 12, 2007

Completed
4 days until next milestone

First Posted

Study publicly available on registry

July 16, 2007

Completed
13.2 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

September 22, 2020

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

September 22, 2020

Completed
Last Updated

November 18, 2020

Status Verified

November 1, 2020

Enrollment Period

13.4 years

First QC Date

July 12, 2007

Last Update Submit

November 17, 2020

Conditions

Keywords

Multiple Endocrine NeoplasiaQuestionnairePsychosocialSurveillance BehaviorsMEN Syndromes

Outcome Measures

Primary Outcomes (1)

  • Profile the demographic, health-related, psychosocial and behavioral characteristics of adults with MEN1 or MEN2.

    3 Years

Study Arms (1)

Multiple Endocrine Neoplasia (MEN)

Patients with multiple endocrine neoplasia (MEN).

Behavioral: Questionnaire

Interventions

QuestionnaireBEHAVIORAL

Mailed packets including cover letter describing purpose of study, study questionnaire, and return envelope.

Also known as: Survey
Multiple Endocrine Neoplasia (MEN)

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodNon-Probability Sample
Study Population

Patients with a diagnosis of MEN1 or MEN2.

You may qualify if:

  • Adults age 18 years or older, with a clinical or genetic diagnosis of MEN1 or MEN2
  • Spouse, Significant Other, or Family Member who is at least 18 years of age and who is related to an individual who is a patient at MDACC and who has been diagnosed with MEN1.
  • Ability to read and write English

You may not qualify if:

  • \) Inability to be contacted via mail (i.e., no contact information on record, incorrect address)

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

University of Texas MD Anderson Cancer Center

Houston, Texas, 77030, United States

Location

Related Links

MeSH Terms

Conditions

Multiple Endocrine NeoplasiaMultiple Endocrine Neoplasia Type 1

Interventions

Surveys and Questionnaires

Condition Hierarchy (Ancestors)

Endocrine Gland NeoplasmsNeoplasms by SiteNeoplasmsNeoplasms, Multiple PrimaryNeoplastic Syndromes, HereditaryGenetic Diseases, InbornCongenital, Hereditary, and Neonatal Diseases and AbnormalitiesEndocrine System Diseases

Intervention Hierarchy (Ancestors)

Data CollectionEpidemiologic MethodsInvestigative TechniquesHealth Care Evaluation MechanismsQuality of Health CareHealth Care Quality, Access, and EvaluationPublic HealthEnvironment and Public Health

Study Officials

  • Susan Peterson, PhD

    M.D. Anderson Cancer Center

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
observational
Observational Model
CASE ONLY
Time Perspective
PROSPECTIVE
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

July 12, 2007

First Posted

July 16, 2007

Study Start

May 1, 2007

Primary Completion

September 22, 2020

Study Completion

September 22, 2020

Last Updated

November 18, 2020

Record last verified: 2020-11

Locations